Utah Medicaid is diabetes-only on GLP-1 coverage
Effects of different corticosteroids on the brain weight and hippocampal neuronal loss in rats
What are the limitations and dosing considerations for tirzepatide in patients with chronic kidney disease?
So thats whats driven this whole premise of higher prices in the marketplace and what the insulin manufacturers did by dropping their price, they really exposed this environment where higher list prices were only benefiting one entity and one entity only, which was the pharmacy benefit management companies
PMID: 41319798): The study showed phase 1b of 18.8% placebo adjusted weight loss at 24 weeks Phase 2 Trial of CT-388 in Adults with Obesity , published in Roche press release / conference presentation (Roche/Genentech investigators, 2026): The study demonstrated placebo adjusted weight loss of 22.5% at 24 mg dose at 48 weeks The study demonstrated reduced BMI below obesity threshold of 54% vs 13% placebo The study showed discontinuation due to AEs of 5.9% vs 1.3% CT-388 research studies and evidence CT-388 dosing protocols CT-388 side effects profile Tirzepatide research guide Semaglutide research guide
Serious Health Concerns: While rare, GLP1's can lead to severe conditions like acute pancreatitis, acute kidney injury, and gallbladder disease
